**Vasa praevia**

**Objectives:** To provide advice on the screening for, diagnosis and management of vasa praevia.

**Target audience:** Health professionals providing maternity care, and patients.

**Values:** The evidence was reviewed by the Women’s Health Committee (RANZCOG), and applied to local factors relating to Australia and New Zealand.

**Validation:** This statement was compared with RCOG and SOGC guidance on this topic.

**Background:** This statement was first developed by Women’s Health Committee in July 2012 and reviewed in July 2016.

**Funding:** The development and review of this statement was funded by RANZCOG.

This statement has been developed and reviewed by the Women’s Health Committee and approved by the RANZCOG Board and Council.

A list of Women’s Health Committee Members can be found in Appendix A.

Disclosure statements have been received from all members of this committee.

**Disclaimer** This information is intended to provide general advice to practitioners. This information should not be relied on as a substitute for proper assessment with respect to the particular circumstances of each case and the needs of any patient. This document reflects emerging clinical and scientific advances as of the date issued and is subject to change. The document has been prepared having regard to general circumstances.

First endorsed by RANZCOG: July 2012  
Current: July 2016  
Review due: July 2019
# Table of contents

1. Patient summary .......................................................................................................................... 3
2. Summary of recommendations ....................................................................................................... 3
3. Introduction .................................................................................................................................... 4
4. Discussion and recommendations ................................................................................................. 4
   4.1 Perinatal mortality and morbidity ............................................................................................... 4
   4.2 Prenatal diagnosis of vasa praevia ............................................................................................. 5
   4.3 Screening for vasa praevia ......................................................................................................... 5
      4.3.1 Universal screening .............................................................................................................. 5
         4.3.1.1 Transvaginal imaging .................................................................................................... 5
         4.3.1.2 Transabdominal imaging .............................................................................................. 6
      4.3.2 Risk factors ......................................................................................................................... 6
      4.3.3 Targeted screening ............................................................................................................. 6
   4.4 Management following antenatal diagnosis ................................................................................. 7
   4.5 Emergency management ......................................................................................................... 8
5. Conclusion ..................................................................................................................................... 8
6. References ...................................................................................................................................... 9
7. Other suggested reading ................................................................................................................ 10
8. Links to other College statements ............................................................................................... 10
9. Patient information ....................................................................................................................... 10
Appendices ....................................................................................................................................... 11
   Appendix A Women’s Health Committee Membership ................................................................. 11
   Appendix B Overview of the development and review process for this statement ..................... 11
   Appendix C Full Disclaimer ........................................................................................................ 13
1. **Patient summary**

Vasa praevia is a rare but potentially serious condition in which blood vessels carrying blood between the placenta and the baby cross over the cervix. These vessels may bleed if the woman goes into labour, if the waters break, or if the cervix opens. Ultrasound examination of women who have risk factors is recommended to determine if vasa praevia is present. If it is found, then special care must be taken in managing the pregnancy and planning the birth.

2. **Summary of recommendations**

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Grade</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommendation 1</td>
<td>Grade</td>
<td>Diagnosing vasa praevia prenatally is associated with a significant reduction in perinatal mortality and morbidity. Consensus-based recommendation</td>
</tr>
<tr>
<td>Recommendation 2</td>
<td>Grade</td>
<td>Transvaginal ultrasound using colour and pulse-wave Doppler to evaluate the internal os and lower uterine segment is the most accurate means to diagnose vasa praevia. Consensus-based recommendation</td>
</tr>
<tr>
<td>Recommendation 3</td>
<td>Grade</td>
<td>Vasa praevia should be diagnosed when there is a fetal vessel either covering or located within 2cm from the internal os. Consensus-based recommendation</td>
</tr>
<tr>
<td>Recommendation 4</td>
<td>Grade</td>
<td>Universal screening of singleton pregnancies with transvaginal ultrasound is not recommended. Consensus-based recommendation</td>
</tr>
<tr>
<td>Recommendation 5</td>
<td>Grade</td>
<td>Where possible, universal screening at the routine mid-trimester scan to locate the placental cord insertion using transabdominal ultrasound and colour Doppler is recommended. Consensus-based recommendation</td>
</tr>
<tr>
<td>Recommendation 6</td>
<td>Grade</td>
<td>The presence of a velamentous cord insertion or other risk factors associated with vasa praevia at the mid-trimester scan should prompt further evaluation by appropriately trained personnel that may include a transvaginal scan. Consensus-based recommendation</td>
</tr>
<tr>
<td>Recommendation 7</td>
<td>Grade</td>
<td>Consider admitting women with prenatally diagnosed vasa praevia to a hospital with appropriate neonatal facilities from around 30 weeks gestation until delivery and administration of corticosteroids for lung maturity. Consensus-based recommendation</td>
</tr>
<tr>
<td>Recommendation 8</td>
<td>Grade</td>
<td>Consider delivery by 35 weeks gestation. Consensus-based recommendation</td>
</tr>
<tr>
<td>Recommendation 9</td>
<td>Grade</td>
<td>Vasa praevia should be suspected in pregnancies with fresh vaginal bleeding (+/- membrane rupture) and acute fetal compromise with heart rate abnormalities such as progressive tachycardia, prolonged bradycardia or sinusoidal pattern. Consensus-based recommendation</td>
</tr>
<tr>
<td>Recommendation 10</td>
<td>Grade</td>
<td>In the presence of bleeding from suspected vasa praevia, delivery by urgent Caesarean section is appropriate with paediatric support for neonatal resuscitation including possible immediate transfusion with O Rh negative Consensus-based recommendation</td>
</tr>
</tbody>
</table>
3. Introduction

Vasa praevia occurs when exposed fetal vessels within the amniotic membranes cover or are in close proximity to the internal cervical os. There are two types: Type 1 vasa praevia occurs with velamentous insertion of the umbilical cord into the placenta and Type II vasa praevia occurs with a velamentous fetal vessel connecting the placenta to a succinuriate placental lobe. Fetal death from rapid exsanguination may occur if the exposed fetal vessels rupture at the time of spontaneous or artificial membrane rupture. Although uncommon with a reported incidence of 1 in 2500, vasa praevia is an important public health issue because of the high perinatal mortality rate associated with unsuspected emergency presentation. Current evidence indicates vastly improved outcomes associated with antenatal diagnosis. However, achieving prenatal diagnosis not clear cut as there are pitfalls with the ultrasound diagnosis of vasa praevia and the role of ultrasound screening in pregnancy lacks a robust evidence base. When vasa praevia is diagnosed antenatally, management guidelines based on the best available evidence recommend strategies to improve outcomes. The Australian Maternity Outcomes Surveillance System (AMOSS) has conducted the first national population based study to describe the incidence, management and outcomes of vasa praevia in Australia. When it is published, this study will be used to further inform guidelines regarding the optimal management of pregnancies complicated by vasa praevia. The aim of management is to minimise emergency presentations with antepartum haemorrhage of fetal origin and so reduce perinatal mortality and morbidity from vasa praevia.

4. Discussion and recommendations

4.1 Perinatal mortality and morbidity

Diagnosing vasa praevia prenatally is associated with significantly improved perinatal survival. One multicentre retrospective cohort study of 155 cases of vasa praevia reported the overall perinatal mortality as 36%. Compared with a 97% (59/61) infant survival in the cases diagnosed prenatally, the survival in the cases not diagnosed prenatally was 44% (41/94). On logistic regression analysis, the variable “prenatal diagnosis” was a significant predictor of survival (OR 102.9; 95%CI 16.2 to 638.3; p<0.001). Corresponding neonatal transfusion rates between prenatally diagnosed and undiagnosed cases were 3.4% and 58.5%, respectively (p<0.001). In another 19 cases in a single centre retrospective cohort study, there were no cases (0/10) of cord blood pH <7 in vasa praevia cases diagnosed prenatally, but 33.3% (3/9) with cord blood pH <7 when not diagnosed prenatally.

<table>
<thead>
<tr>
<th>Recommendation 1</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosing vasa praevia prenatally is associated with a significant reduction in perinatal mortality and morbidity.</td>
<td>Consensus-based recommendation</td>
</tr>
</tbody>
</table>
4.2 Prenatal diagnosis of vasa praevia

Vasa praevia was first diagnosed antenatally by real-time ultrasound in 1987\(^8\) and colour Doppler in 1990.\(^9\) Abdominal wall scarring, obesity, or an empty maternal bladder may compromise trans abdominal assessment of the lower segment.\(^10,11\) A recent systematic review of the accuracy of ultrasound in diagnosing vasa praevia, concluded that ultrasound diagnosis is highest when performed transvaginally in combination with colour Doppler. Overall in the eight included studies, the antenatal detection rates varied from 53 to 100%. However, analysis of the only two prospective studies included, showed that all cases of vasa praevia were detected (sensitivity 100%) with a specificity of 99-99.8% when transvaginal colour Doppler was performed.\(^12\)

It must be recognised that not all cases of vasa praevia can be diagnosed antenatally.\(^11\) Transvaginally the direction of the fetal vessels may inhibit diagnosis. False positives are not uncommon and can arise from motion artifacts, umbilical cord (funic) presentation or a marginal placental sinus.\(^10,11,13\)

Using a transvaginal approach to image the internal cervical os and lower uterine segment, the diagnostic criteria for VP includes:

- Visualising aberrant linear or tubular echolucent structures with 2D imaging\(^10\)
- Demonstrating blood flow in these structures using colour or power Doppler\(^13\)
- Demonstrating umbilical arterial/venous Doppler waveforms using pulse wave Doppler\(^4\)
- Aberrant vessels located over or within 2cm of the internal os attached to the inner perimeter of the fetal membranes\(^14\)

<table>
<thead>
<tr>
<th>Recommendation 2</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transvaginal ultrasound using colour and pulse-wave Doppler to evaluate the internal os and lower uterine segment is the most accurate means to diagnose vasa praevia.</td>
<td>Consensus-based recommendation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendation 3</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vasa praevia should be diagnosed when there is a fetal vessel either covering or located within 2cm from the internal os.</td>
<td>Consensus-based recommendation</td>
</tr>
</tbody>
</table>

4.3 Screening for vasa praevia

There is no consensus from the international obstetric community about screening for prenatal detection of vasa praevia. Only the Society of Obstetricians and Gynaecologists of Canada (SOGC) and Royal College of Obstetricians and Gynaecologists (RCOG) have published practice guidelines on the diagnosis and management of vasa praevia and they differ in their recommendations for screening.\(^4,5\) Because there are no large prospective trials, screening strategies rely on data combined from many small case series. Different strategies have been considered and require informed debate.

4.3.1 Universal screening

4.3.1.1 Transvaginal imaging

Vasa praevia is a serious health problem and diagnosis by transvaginal imaging with colour Doppler is accurate. However, the condition is uncommon and there is no robust evidence that universal screening of the general population using routine transvaginal imaging would be accurate, practical or improve perinatal outcomes.\(^11\) In addition, a cost-utility analysis performed in Canada in 2010 concluded that routine transvaginal screening for vasa praevia in singleton pregnancies at the mid trimester obstetric scan is not cost-effective.\(^15\) Concordantly, universal screening by routine transvaginal ultrasound is not recommended by either the SOGC or the RCOG.\(^4,5\)
4.3.1.2 Transabdominal imaging

The occurrence of vasa praevia in the absence of a velamentous cord insertion is negligible. Therefore, routine screening of all pregnancies by transabdominal ultrasound to ascertain either a velamentous insertion of the umbilical cord into the placenta or the presence of a multi-lobed placenta has been proposed. Velamentous placental cord insertion occurs in approximately 1% of singleton pregnancies. Detection would enable evaluation of the lower segment for the presence of a vasa praevia that occurs in only 2% of velamentous placental cord insertions (see Targeted screening).

The feasibility of assessing the placental cord insertion has been studied in both the first and second trimesters with no advantage being found in first trimester assessment. Prospective studies at the mid trimester anomaly scan have demonstrated that placental cord insertions are quickly identifiable using colour Doppler without further training in ≥ 99% pregnancies. The accuracy of routine mid trimester screening to detect velamentous cord insertions have been reported in a prospective study of 3446 cases with a sensitivity of 62.5%, positive predictive value of 100% and negative predictive value of 99.5%.

4.3.2 Risk factors

In addition to its association with velamentous cord insertion, vasa praevia is also associated with bi-lobed and succenturiate placental abnormalities, placenta praevia, a history of a low-lying placenta in the second trimester, IVF and multiple pregnancy. A retrospective analysis of these risk factors in 12063 deliveries from a single centre that routinely screens for vasa praevia, determined which of these variables were independent risk factors for vasa praevia. Second trimester placenta praevia, with an odds ratio of 22.86 (95%CI 5.57-93.78) and bi-lobed or succenturiate placenta, with an odds ratio of 22.11 (95%CI 1.92-253.84) are the most significant risk factors. IVF is a significant risk factor with an odds ratio of 7.75 (95%CI 1.99-30.10) and increases the incidence of vasa praevia to as high as 1 in 200. Multiple pregnancy was not an independent risk factor.

4.3.3 Targeted screening

Targeted ultrasound screening for vasa praevia is advocated by many authors. A comprehensive literature review identified 28 cases of prenatally diagnosed vasa praevia in 17 publications over 16 years and has advocated screening ultrasound and suggested the following screening algorithm. All pregnancies are screened abdominally at the mid trimester ultrasound for the location of the lower margin of the placenta and the location of the placental cord insertion. If these are greater than 2 cm from the internal ost, no further assessment is required. If there is a low lying, succenturiate or bi-lobed placenta, a velamentous cord insertion or an IVF or multiple pregnancy, then an abdominal scan of the cervix is performed with colour Doppler. If there are any suspicious findings or poor visualisation, then a transvaginal scan is performed to optimise the diagnosis. Concordant with this algorithm, the 2010 cost-utility analysis was also in favour of targeted screening. This study concludes that the use of transabdominal colour Doppler at all singleton mid trimester ultrasound scans with targeted transvaginal scans in the presence of velamentous cord insertions, placental abnormalities or IVF pregnancies is cost effective. Screening all twin pregnancies with transvaginal ultrasound was found to be cost-effective as the QALY-gained was not different between twins resulting from IVF and all twins. SOGC recommends targeted transvaginal screening in the presence of risk factors. The RCOG does not recommend any screening for vasa praevia but acknowledges that some centres, based on their case mix, screening those with risk factors may be justifiable.

<table>
<thead>
<tr>
<th>Recommendation 4</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Universal screening of singleton pregnancies with transvaginal ultrasound is not recommended</td>
<td>Consensus-based recommendation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendation 5</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Where possible, universal screening at the routine mid-trimester scan to locate the placental cord insertion using transabdominal ultrasound and colour Doppler is recommended.</td>
<td>Consensus-based recommendation</td>
</tr>
</tbody>
</table>
4.4 Management following antenatal diagnosis

There are no clinical trials to inform the optimal management in cases of confirmed vasa praevia and because the severity of the outcome, are not ethically justifiable. Consequently, the best management strategies are based on retrospective case series and consensus views. For confirmed cases of vasa praevia with no bleeding, both SOGC and RCOG clinical guidelines suggest the following management:

- Admission to hospital from 30 weeks gestation until the time of delivery to expedite urgent emergency delivery in the event of membrane rupture, vaginal bleeding or preterm labour;
- Administration of corticosteroids for fetal lung maturation in anticipation of preterm delivery;
- Admission and delivery in a hospital with paediatric expertise and appropriate level of neonatal care;
- Delivery by elective caesarean section prior to the onset of labour.

Other options include:

- Outpatient management of select asymptomatic singleton cases with a long closed cervix on serial transvaginal ultrasound scans and a negative fetal fibronectin. This option is supported by a retrospective cohort study published in 2013 which reported a 4% risk of preterm emergency delivery in singleton pregnancies diagnosed prenatally.
- The optimal gestation at which to admit patients with a prenatal diagnosis of vasa praevia may depend on the circumstances of the patient and availability of the appropriate inpatient facilities.
- Transvaginal ultrasound with colour Doppler to map fetal vessels preoperatively to avoid iatrogenic laceration and intraoperative fetal haemorrhage.

The optimal gestation at which to deliver is balanced by the risks of perinatal mortality and morbidity from ruptured vasa praevia and the risks associated with iatrogenic prematurity. The largest published series of prenatally diagnosed cases reported a mean gestational age at delivery of 34.9 +/- 2.5 weeks but 27.9% were emergency caesarean sections for bleeding, labour or ruptured membranes. This study demonstrated on logistic regression analysis, the variable “gestational age at delivery” was the other significant predictor of survival besides “prenatal diagnosis” (OR 0.77; 95%CI 0.64 to 0.93; p<0.01). The mean gestation at delivery of undiagnosed cases, and that associated with a 56% perinatal mortality, was 38.2 +/- 2.1 weeks. These authors claim that delivery at later gestational ages may negate the benefit of prenatal diagnosis.

To further inform practise, a decision analysis published with 11 strategies for timing delivery weekly from 32 to 39 weeks gestation factored in lifetime risks of death, respiratory distress syndrome, cerebral palsy and neurodevelopmental disability. This indicated that following prenatal diagnosis of vasa praevia, the preferred timing for elective caesarean section is 34 or 35 weeks gestation under most but not all circumstances. Under no clinical circumstances was there a benefit to be gained by expectant management beyond 37 weeks gestation.

Recommendation 6
The presence of a velamentous cord insertion, succenturiate lobe or other risk factors associated with vasa praevia at the mid-trimester scan should prompt further evaluation by appropriately trained personnel that may include a transvaginal scan.

Grade
Consensus-based recommendation

Recommendation 7
Consider admitting women with prenatally diagnosed vasa praevia to a hospital with appropriate neonatal facilities from around 30 weeks gestation until delivery and administration of corticosteroids for lung maturity.

Grade
Consensus-based recommendation

Recommendation 8
Consider delivery by 35 weeks gestation.

Grade
Consensus-based recommendation
4.5 Emergency management

While antenatal diagnosis optimises outcome among women with known vasa praevia, undiagnosed cases will still occur. Vasa praevia should be suspected in pregnancies with fresh vaginal bleeding (+/- membrane rupture) and acute fetal compromise with heart rate abnormalities such as progressive tachycardia, prolonged bradycardia, sinusoidal pattern or fetal death. While bedside tests are available to establish if vaginal bleeding is of fetal origin, accessing these tests is usually too slow to be of any clinical use. Because of the small fetal blood volume, the loss of relatively small amounts of blood may lead to fetal shock. The prognosis associated with bleeding from a fetal vessel is poor. Urgent emergency Caesarean section to effect rapid delivery and paediatric support for neonatal resuscitation including immediate transfusion with O Rh negative blood may be lifesaving. The rate of transfusion in surviving neonates of vasa praevia not diagnosed antenatally is reported as 58.5%. Neonatal paediatricians need to be advised of the suspected diagnosis of bleeding vasa praevia before Caesarean section so that they can make the required preparations to resuscitate an infant whose circulating blood volume is depleted.

<table>
<thead>
<tr>
<th>Recommendation 9</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vasa praevia should be suspected in pregnancies with fresh vaginal bleeding (+/- membrane rupture) and acute fetal compromise with heart rate abnormalities such as progressive tachycardia, prolonged bradycardia or sinusoidal pattern.</td>
<td>Consensus-based recommendation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendation 10</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>In the presence of bleeding from suspected vasa praevia, delivery by urgent Caesarean section is appropriate with paediatric support for neonatal resuscitation including possible immediate transfusion with O Rh negative blood. Paediatricians should be advised of the suspected fetal blood loss prior to Caesarean section.</td>
<td>Consensus-based recommendation</td>
</tr>
</tbody>
</table>

5. Conclusion

Vasa previa is an uncommon but potentially life threatening condition for the fetus / neonate. Perinatal outcomes improve significantly when antenatal diagnosis enables planned management that includes elective Caesarean section by 35 weeks gestation before the onset of labour. Universal screening to locate the placental cord insertion at the routine mid trimester scan enables further assessment of a velamentous cord insertion by appropriately trained personnel using colour Doppler and transvaginal imaging. In the event of an emergency Caesarean section for a suspected vasa previa, paediatricians should be informed and prepared for immediate neonatal transfusion with O Rh negative blood in the event of haemorrhagic shock.
6. References


5. RCOG Green Top guideline 27


7. **Other suggested reading**

RCOG Green-top guideline 27; Placenta praevia, placenta praevia accreta and vasa praevia: diagnosis and management.
Available at: [https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg27/](https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg27/)

8. **Links to other College statements**

- Measurement of Cervical Length in Pregnancy (C-Obs 27)
- Evidence-based Medicine, Obstetrics and Gynaecology (C-Gen 15)

9. **Patient information**

A range of RANZCOG Patient Information Pamphlets can be ordered via:
[https://www.ranzcog.edu.au/Womens-Health/Patient-Information-Guides/Patient-Information-Pamphlets](https://www.ranzcog.edu.au/Womens-Health/Patient-Information-Guides/Patient-Information-Pamphlets)
Appendices

Appendix A Women’s Health Committee Membership

<table>
<thead>
<tr>
<th>Name</th>
<th>Position on Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professor Stephen Robson</td>
<td>Chair and Board Member</td>
</tr>
<tr>
<td>Dr James Harvey</td>
<td>Deputy Chair and Councillor</td>
</tr>
<tr>
<td>Associate Professor Anusch Yazdani</td>
<td>Member and Councillor</td>
</tr>
<tr>
<td>Associate Professor Ian Pettigrew</td>
<td>Member and Councillor</td>
</tr>
<tr>
<td>Dr Ian Page</td>
<td>Member and Councillor</td>
</tr>
<tr>
<td>Professor Yee Leung</td>
<td>Member of EAC Committee</td>
</tr>
<tr>
<td>Professor Sue Walker</td>
<td>General Member</td>
</tr>
<tr>
<td>Dr Lisa Hui</td>
<td>General Member</td>
</tr>
<tr>
<td>Dr Joseph Sgroi</td>
<td>General Member</td>
</tr>
<tr>
<td>Dr Marilyn Clarke</td>
<td>General Member</td>
</tr>
<tr>
<td>Dr Donald Clark</td>
<td>General Member</td>
</tr>
<tr>
<td>Associate Professor Janet Vaughan</td>
<td>General Member and Councillor</td>
</tr>
<tr>
<td>Dr Benjamin Bopp</td>
<td>General Member</td>
</tr>
<tr>
<td>Associate Professor Kirsten Black</td>
<td>General Member</td>
</tr>
<tr>
<td>Dr Jacqueline Boyle</td>
<td>Chair of the ATSIWHC</td>
</tr>
<tr>
<td>Dr Martin Byrne</td>
<td>GPOAC representative</td>
</tr>
<tr>
<td>Ms Catherine Whitby</td>
<td>Community representative</td>
</tr>
<tr>
<td>Ms Sherryn Elworthy</td>
<td>Midwifery representative</td>
</tr>
<tr>
<td>Dr Michelle Proud</td>
<td>Trainee representative</td>
</tr>
</tbody>
</table>

Appendix B Overview of the development and review process for this statement

i. Steps in developing and updating this statement

This statement was originally developed in July 2012 and was most recently reviewed in March 2016. The Women’s Health Committee carried out the following steps in reviewing this statement:

- Declarations of interest were sought from all members prior to reviewing this statement.
- Structured clinical questions were developed and agreed upon.
- An updated literature search to answer the clinical questions was undertaken.
- At the March 2016 face-to-face committee meeting, the existing consensus-based recommendations were reviewed and updated (where appropriate) based on the available body of evidence and clinical expertise. Recommendations were graded as set out below in Appendix B part iii)

ii. Declaration of interest process and management

Declaring interests is essential in order to prevent any potential conflict between the private interests of members, and their duties as part of the Women’s Health Committee.

A declaration of interest form specific to guidelines and statements was developed by RANZCOG and approved by the RANZCOG Board in September 2012. The Women’s Health Committee members were required to declare their relevant interests in writing on this form prior to participating in the review of this statement.
Members were required to update their information as soon as they become aware of any changes to their interests and there was also a standing agenda item at each meeting where declarations of interest were called for and recorded as part of the meeting minutes.

There were no significant real or perceived conflicts of interest that required management during the process of updating this statement.

iii. Grading of recommendations

Each recommendation in this College statement is given an overall grade as per the table below, based on the National Health and Medical Research Council (NHMRC) Levels of Evidence and Grades of Recommendations for Developers of Guidelines. Where no robust evidence was available but there was sufficient consensus within the Women’s Health Committee, consensus-based recommendations were developed or existing ones updated and are identifiable as such. Consensus-based recommendations were agreed to by the entire committee. Good Practice Notes are highlighted throughout and provide practical guidance to facilitate implementation. These were also developed through consensus of the entire committee.

<table>
<thead>
<tr>
<th>Recommendation category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence-based</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>Body of evidence can be trusted to guide practice</td>
</tr>
<tr>
<td>B</td>
<td>Body of evidence can be trusted to guide practice in most situations</td>
</tr>
<tr>
<td>C</td>
<td>Body of evidence provides some support for recommendation(s) but care should be taken in its application</td>
</tr>
<tr>
<td>D</td>
<td>The body of evidence is weak and the recommendation must be applied with caution</td>
</tr>
<tr>
<td>Consensus-based</td>
<td>Recommendation based on clinical opinion and expertise as insufficient evidence available</td>
</tr>
<tr>
<td>Good Practice Note</td>
<td>Practical advice and information based on clinical opinion and expertise</td>
</tr>
</tbody>
</table>
Appendix C Full Disclaimer

This information is intended to provide general advice to practitioners, and should not be relied on as a substitute for proper assessment with respect to the particular circumstances of each case and the needs of any patient.

This information has been prepared having regard to general circumstances. It is the responsibility of each practitioner to have regard to the particular circumstances of each case. Clinical management should be responsive to the needs of the individual patient and the particular circumstances of each case.

This information has been prepared having regard to the information available at the time of its preparation, and each practitioner should have regard to relevant information, research or material which may have been published or become available subsequently.

Whilst the College endeavours to ensure that information is accurate and current at the time of preparation, it takes no responsibility for matters arising from changed circumstances or information or material that may have become subsequently available.